family with sequence similarity 81 member AGenealiases: []
Q-omics provides the consensus-scored FAM81A profile across patient tissues and cancer cell-line models. FAM81A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM81A is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FAM81A RNA expression shows 17,531 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where FAM81A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM81A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM81A survival associations across molecular data types. FAM81A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM81A RNA expression–survival associations across cancer types. High FAM81A expression shows unfavorable associations in LUAD, UVM, PAAD, ESCA and LAML, but favorable associations in UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM81A RNA expression.
This table summarizes FAM81A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM81A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM81A shows lower tumor expression in KIRC and higher tumor expression in LUAD, STAD, LIHC, COAD and BLCA. The KIRC box plot shows higher FAM81A RNA expression in normal versus tumor tissue (log2 FC = −2.115, t-test p < 0.001).
This table shows molecular features associated with FAM81A in patient tissues and cancer cell lines. In patient samples, FAM81A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM81A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
